Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problemsSeattle-based Ozette announced a $26 million Series A on July 28, 2022, led by Madrona Ventures and backed by M12, Microsoft’s venture fund, and other investors. The company planned to use the financing to expand software for analyzing single-cell immune data and develop an immunology lab. This is a historical funding announcement—not a new round or a Microsoft acquisition.
What Ozette raised and who invested
The round was a $26 million Series A led by Madrona Ventures. Participants named in the announcement were Cercano Management, formerly Vulcan Capital; M12, Microsoft’s venture fund; Alexandria Venture Investments; OCV Partners; and Duke University. Ozette had previously raised a $6 million seed round led by Madrona, according to GeekWire’s 2022 report.
M12’s participation means Microsoft’s venture fund invested; it does not, by itself, establish a Microsoft commercial partnership or acquisition. The $26 million figure, investor list and intended uses were announced by Ozette on July 28, 2022.
What the company said the money would support
- Hiring and team growth.
- Expansion from immune-cell protein analysis toward a broader multiomic platform combining proteomics and transcriptomics.
- Exploration of spatial biology and development of an immunology laboratory.
These were announced plans, not proof that every milestone was completed. Ozette’s current site now presents software products and lab services, but does not establish that each element of the 2022 roadmap was delivered exactly as originally envisioned.
Recommended Free Tools
#1 Best Overall
What Ozette does—and why immune-cell analysis is challenging
Ozette is a life-sciences technology company focused on computational analysis of immune-system data. The company says its work grew out of research at Fred Hutchinson Cancer Center and that it was incubated at the Allen Institute for Artificial Intelligence (AI2); its origins and Seattle connections are described on its About Us page. The 2022 coverage named Ali Ansary, Greg Finak, Evan Greene and Raphael Gottardo among the company’s founders or scientific contributors.
Flow cytometry measures physical and molecular characteristics of cells as they pass through an instrument. Researchers can label cells with antibodies to measure many proteins on individual cells. Spectral flow cytometry captures broader emission information, supporting larger panels, but it also creates complex data that must be processed and interpreted. In this context, “single-cell proteomics” means measuring protein markers cell by cell; single-cell transcriptomics measures RNA expression at that resolution.
A common analysis method is manual gating: an analyst inspects plots and draws boundaries, or gates, to separate populations based on measured markers. This can be appropriate for known, prespecified populations, but repeated manual analysis can take substantial time and may be less suited to searching very large datasets for rare or unexpected patterns. A computational discovery method instead attempts to identify groupings without requiring every population to be specified in advance. A discovered cluster, however, is a candidate for scientific interpretation—not automatically a validated cell type or clinical finding.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
How the platform is intended to work
Ozette describes a workflow that begins with cytometry files and combines preprocessing, analysis and human review. Its platform page describes FCS file ingestion, adaptive spectral unmixing where relevant, cell-population analysis, interactive review and approval, visualization, dashboards and exports.
- Generate data: A lab produces cytometry or related single-cell measurements. The exact assay and supported instrument workflow matter; different modalities do not share identical preprocessing needs.
- Upload and prepare: Files in FCS format enter the platform. For spectral data, unmixing separates overlapping signal contributions before downstream analysis.
- Identify populations or endpoints: Algorithms help classify populations, explore candidate cell groups or quantify selected biomarkers.
- Review: Researchers inspect visualizations and gates, then review and approve results. Ozette presents the platform as assisted analysis rather than an autonomous substitute for scientific judgment.
- Export and interpret: Teams can produce figures, dashboards or summary outputs for research and development workflows. Biological interpretation and validation remain the research team’s responsibility.
Current product categories and service options
Ozette’s current product materials organize its software into three tiers, with a separate lab-service offering. The names describe the company’s positioning; prospective users should confirm supported assays, workflows and commercial terms for their own project.
| Offering | Stated role | Best understood as |
|---|---|---|
| Resolve | Adaptive spectral unmixing | Preparation of spectral data before downstream analysis, with the aim of reducing artifacts and manual compensation work. |
| Endpoints | Automated biomarker analysis | Quantification of selected biomarkers for applications such as trial endpoints, dose finding, safety and efficacy analysis. |
| Discovery | Cell-population discovery and annotation | Exploratory analysis intended to find rare, low-abundance or previously uncharacterized phenotypes. |
| Ozette Lab | Managed laboratory and analysis service | A more integrated route for teams seeking data generation and analysis; Ozette describes customizable assays, a quality system and GCLP-oriented workflows. |
The company advertises self-serve software as well as managed services, including a license-plus-pay-per-file model and a free Resolve trial. Public dollar prices were not stated on the inspected platform and company pages; the trial should not be assumed to include full Endpoints or Discovery capabilities.
What evidence supports the scientific claims?
The 2022 announcement said Ozette technology had been used in immunological studies and that company-supported work had examined more than $100 million in clinical-trial data. That figure is a company-reported description in the funding announcement, not an independently audited measure of accuracy, scale or clinical benefit.
GeekWire connected the company’s methods to a 2021 publication on automated resolution of immune-cell populations and associations with drug response, as well as work involving HIV and COVID-19. It also discussed a Nature-published study identifying a T-cell population associated with suppression of immune responses in solid tumors. Ozette’s cancer drug-development case study describes related research context. These examples support research use and biomarker exploration; they do not establish that Ozette’s platform improves patient outcomes, causes a drug discovery, or produces an approved therapy.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →The company’s 2022 claim that analysis that might take months manually could be reduced to days should likewise be treated as a company performance claim, not a universal comparative benchmark. Its meaning depends on the manual workflow, assay and panel, dataset size, and whether data cleaning, quality control, human review and biological interpretation are included. Faster first-pass analysis does not eliminate validation.
Rank #4
Why investors may have seen an opportunity
The investment thesis can reasonably be read as a bet on the growing volume and complexity of single-cell measurements, the demand for biomarkers in oncology and immunotherapy, and the difficulty of analyzing large trial datasets consistently. A platform that connects data processing, population analysis and review could appeal to biopharma biomarker teams, clinical-trial organizations, contract research organizations and academic immunology labs—especially those without deep in-house computational immunology capacity. This is an interpretation of the company’s product and funding plans, not a quoted investor rationale.
Ozette’s Seattle identity also links academic immunology research with the region’s technology ecosystem. Its Fred Hutch and AI2 origins, alongside a team described in the 2022 coverage as having experience at companies including Genentech, Google, Microsoft and Amazon, help explain that mix of scientific and software ambitions.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Where the platform may fit—and where it may not
Potential fit
- Large or longitudinal high-dimensional cytometry datasets that are burdensome to analyze manually.
- Clinical-trial biomarker programs seeking consistent analysis across studies or sites.
- Exploratory projects looking for rare or previously uncharacterized immune-cell populations.
- Organizations interested in a managed sample-to-analysis workflow rather than assembling separate tools and services.
Potential mismatch
- Routine clinical diagnosis, treatment recommendations or other patient-care decisions.
- Small projects that existing manual workflows handle adequately.
- Teams that require fully local, offline analysis or cannot use cloud services without additional contractual review.
- Projects using modalities or instruments outside the platform’s supported workflows.
- Work that requires causal biological conclusions from descriptive population analysis alone.
Ozette’s About Us page says its data are intended for exploratory research and should not be used for clinical decisions such as diagnosis, prevention, monitoring or treatment. The platform is not presented as a clinical diagnostic tool.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteBest Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Questions buyers should resolve before adopting it
Automated discovery can broaden and standardize an analysis, but a computationally identified cluster needs biological scrutiny. Depending on the question, researchers may need replicate cohorts, orthogonal assays or functional experiments to determine whether a pattern is robust and meaningful. Prespecified endpoints for a development program also pose a different problem from open-ended exploratory discovery; teams should establish how the workflow supports reproducibility and any required validation before relying on outputs.
For a cloud-based workflow, buyers should also review data residency, access controls, audit trails, retention and deletion terms, ownership of uploaded data and derived models, and validation documentation. Ozette advertises secure cloud handling and reviewable, auditable workflows on its platform page, but the public material cited here does not establish the details needed to assess every sponsor or institutional compliance requirement.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
